# Schizophrenia Study In Adults

> **NCT00049946** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 231 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** talnetant
- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00049946
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2003-04
- **Final completion:** 2003-04
- **Target enrollment:** 231 (—)
- **Last updated:** 2017-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049946, "Schizophrenia Study In Adults". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00049946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*